ALTHX.PA stock +19.51% to €2.45 on EURONEXT 28 Jan 2026: volume spike
ALTHX.PA stock jumped 19.51% to €2.45 on EURONEXT at market close on 28 Jan 2026. Trading volume surged to 502039.00 shares versus an average of 89510.00, signaling strong intraday buying pressure. The move pushed the share price above its 50-day average of €1.96 and 200-day average of €1.76, attracting momentum traders in Europe’s healthcare segment. Meyka AI’s real-time screens flagged ALTHX.PA stock as a top gainer and flagged a mix of speculative flows and improving technicals as drivers for the jump.
Price action: ALTHX.PA stock performance and intraday range
Theranexus SA (ALTHX.PA) closed at €2.45, up €0.40 from the prior close of €2.05 with a session range €2.22–€2.60. Volume was 502039.00, a relative volume of 2.33, indicating outsized participation compared with the average daily volume of 89510.00.
The stock sits well below its 52-week high of €3.66 and well above its 52-week low of €0.26, leaving meaningful upside for momentum traders and high volatility for risk managers.
News and catalysts behind the move for ALTHX.PA stock
The price jump followed sector-level attention and comparative charts circulating on financial sites, which highlighted Theranexus versus peers and drew fresh interest from small-cap healthcare investors. Investing.com ZA published comparative performance that traders referenced ahead of the close.
Company fundamentals remain clinical-stage: lead programs THN102, THN201 and THN101 keep valuation tied to trial outcomes rather than sales, so clinical updates or partnership chatter typically move the stock.
Fundamentals and valuation for ALTHX.PA stock
Key financials show EPS -0.34 and a negative P/E of -6.62, reflecting losses while the company is in development stage. Market capitalization is €21196667.00 with 9420741.00 shares outstanding, limiting free float and amplifying price moves on volume spikes.
Other ratios: price averages 50/200 at €1.96 and €1.76, price to sales and price to book metrics are extreme due to minimal revenues and negative equity. Current ratio is 0.70, and research intensity remains high at 38.14% of revenue.
Technical picture and trading signals for ALTHX.PA stock
Momentum and trend indicators are mixed: RSI at 53.80 and MACD slightly positive (MACD 0.05, signal 0.04) suggest neutral-to-mild bullish momentum. Bollinger Bands show a middle at €2.10 with upper band €2.33, placing the close above the middle band.
Support sits near the 50-day average €1.96 and near €2.22 intraday low; resistance clusters at the 52-week high €3.66 and recent highs around €2.60. Traders should note ATR 0.13 for sizing and stop placement.
Meyka AI grade and ALTHX.PA stock forecast
Meyka AI rates ALTHX.PA with a score out of 100: 61.55 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects monthly €1.94, quarterly €2.77, and yearly €3.61. Compared with the current price €2.45, the model implies a short-term upside of 13.06% to the quarterly figure and a 12‑month upside of 47.20% to the yearly target. Forecasts are model-based projections and not guarantees.
Risks and catalysts shaping ALTHX.PA stock outlook
Primary risks are clinical trial outcomes, cash runway given negative cash flow metrics, and thin liquidity that can magnify moves—current ratio 0.70 and free cash flow per share negative. Company-level news or failed trials would likely drive sharp declines.
Key catalysts include Phase II readouts for THN102, partnership announcements, or positive regulatory signals. Given the company’s small market cap and research focus, news flow will remain the dominant price driver.
Final Thoughts
Theranexus SA (ALTHX.PA) ended the session on EURONEXT up 19.51% to €2.45 on 28 Jan 2026, led by a volume surge of 502039.00 shares and momentum buying that pushed the stock above its 50-day average. From a fundamentals view, EPS -0.34 and negative P/E reflect a clinical-stage biotech with valuation tied to trial news rather than revenue metrics. Meyka AI’s forecast model projects a 12-month target of €3.61, implying 47.20% upside versus the current price; a more conservative 3-month projection is €2.77 (+13.06%). Traders should balance upside potential against liquidity risk and cash-runway metrics. These findings come from Meyka AI’s AI-powered market analysis platform and are model-based projections, not guarantees. Always match position sizing to trial-risk exposure and remember these grade and forecast outputs are informational and not financial advice.
FAQs
Why did ALTHX.PA stock jump today?
ALTHX.PA stock rose on 28 Jan 2026 due to heavy intraday volume and renewed interest after comparative performance charts circulated. In small-cap biotech, speculative flows and sector attention often trigger sharp moves rather than immediate fundamental changes.
What is Meyka AI’s price outlook for ALTHX.PA stock?
Meyka AI’s model projects €3.61 in 12 months and €2.77 at three months. Versus today’s €2.45, that implies potential upside, but these are model-based projections and not guarantees.
What are the main risks to ALTHX.PA stock investors should watch?
Key risks include clinical trial failures, tight liquidity (market cap €21196667.00) and negative cash flow metrics. News-driven volatility is high for this clinical-stage company, so monitor trial calendars and cash-runway updates.
Is ALTHX.PA stock a buy after the 19.51% move?
After the rise, Meyka AI assigns a B / HOLD grade reflecting mixed fundamentals and upside potential. Investors should weigh trial-readout timing, cash runway, and personal risk tolerance before increasing exposure.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
